Exendin-4 Fc fusion protein （）

Phase 3Small molecule

Exendin-4 Fc fusion protein （） is one of 35 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

Competition

Competitive Landscape

286 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Exendin-4 Fc fusion protein （）

BBeijing Dongfang Biotech Co., Ltd.

Phase 3

1 2

Trulicity

Eli Lilly

Preclinical

2 3

Byetta

AstraZeneca

Preclinical

2 4

Galvus

Novartis

Preclinical

1 5

NOVOLIN R

Novo Nordisk

Preclinical

1 6

Edarbi

Takeda

Preclinical

1 7

Paxil CR

GSK

Preclinical

1 8

Simponi

Johnson & Johnson

Preclinical

1 9

Insulin 320

Tanzeum

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Diabetes Mellitus

NCT06257966

Clinical

Trials by Indication[1]

Efficacy1 trial

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Active, not recruiting·BBeijing Dongfang Biotech Co., Ltd.·Phase 3·NCT06254014·270 enrolled

Overweight1 trial

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

Completed·BBeijing Dongfang Biotech Co., Ltd.·Phase 1·NCT06247748·28 enrolled

Diabetes Mellitus1 trial

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Active, not recruiting·BBeijing Dongfang Biotech Co., Ltd.·Phase 3·NCT06257966·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Exendin-4 Fc fusion protein （）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exendin-4 Fc fusion protein （） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exendin-4 Fc fusion protein （）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Dongfang Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Dongfang Biotech Co., Ltd.

Exendin-4 Fc fusion protein （）

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Efficacy1 trial

Overweight1 trial

Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News